Allo-HCT in CLL after multiple pathway inhibitors. Group Chronic Malignancies Working Party (CMWP) Principal investigator Michel van Gelder/Olivier Tournilhac
Outcomes following the use of PTCy in URD allo-HCT for CML Group Chronic Malignancies Working Party (CMWP) Principal investigator Guillermo Orti
Autologous Peripheral Blood Stem Cell Mobilisation Techniques, Stem Cell Yields and Practice Variation-By-Country in Patients with Myeloma Undergoing First Autologous Stem Cell Transplants in EBMT Centres. Group Chronic Malignancies Working Party (CMWP) Principal investigator Patrick Hayden
Outcomes of Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) in Patients with CALR-Mutated Myelofibrosis compared to those patients with a JAK2-mutation. Group Chronic Malignancies Working Party (CMWP) Principal investigator Juan Carlos Hernández-Boluda
GvHD Prophylaxis Incorporating Methotrexate in Allo-HCT for Chronic Myeloid Malignancies and sAML: A Retrospective Analysis from the CMWP of the EBMT. Group Chronic Malignancies Working Party (CMWP) Principal investigator Thomas Luft
Survey Non-Tuberculous Mycobacterial infections post-hematopoietic stem cell transplantation Group Infectious Diseases Working Party (IDWP) Principal investigator Maria Stamouli
Daratumumab for PRCA after alloSCT Group Transplant Complications Working Party (TCWP) Type of Stem Cell Treatment Principal investigator Nico Gagelmann
Outcomes of PT-CY in elderly AML/MDS Diseases Group Transplant Complications Working Party (TCWP) Type of Stem Cell Treatment Principal investigator Maria Queralt Salas
Immune Checkpoint Inhibitors for solid tumors after allogeneic stem cell transplanation Diseases Group Transplant Complications Working Party (TCWP) Principal investigator Jan Brijs
Pre-transplantation diabetes and obesity and acute graft-versus-host disease after allogeneic hematopoietic cell transplantation Group Transplant Complications Working Party (TCWP) Principal investigator Lars Klingen Gjaerde
Chronic GVHD over time - a multicenter retrospective study Diseases Group Transplant Complications Working Party (TCWP) Principal investigator Drazen Pulanic
Steroid-free first line treatment of moderate and severe chronic GVHD - restrospective study Diseases Group Transplant Complications Working Party (TCWP) Principal investigator Ivan Moiseev